Depot risperidone-induced adverse metabolic alterations in
female rats

J 2017

Depot risperidone-induced adverse metabolic alterations in female rats

HORSKÁ, Kateřina, Jana RUDÁ, Michal KARPISEK, Radka OPATŘILOVÁ, Pavel SUCHÝ et. al.

Basic information

Original name

Depot risperidone-induced adverse metabolic alterations in female rats

Authors

HORSKÁ, Kateřina (203 Czech Republic), Jana RUDÁ (203 Czech Republic, guarantor, belonging to the institution), Michal KARPISEK (203 Czech Republic), Radka OPATŘILOVÁ (203 Czech Republic), Pavel SUCHÝ (203 Czech Republic) and Hana KOTOLOVÁ (203 Czech Republic)

Edition

Journal of Psychopharmacology, London, SAGE Publications Ltd. 2017, 0269-8811

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.738

RIV identification code

RIV/00216224:14110/17:00096183

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1177/0269881117691466

UT WoS

000400179400009

Keywords in English

Adipokine; depot risperidone; leptin; lipid profile; Sprague-Dawley rats

Abstract

V originále

Atypical antipsychotics are associated with adverse metabolic effects including weight gain, increased adiposity, dyslipidaemia, alterations in glucose metabolism and insulin resistance. Increasing evidence suggests that metabolic dysregulation precedes weight gain development. The aim of this study was to evaluate alterations in adipokines, hormones and basic serum biochemical parameters induced by chronic treatment with depot risperidone at two doses (20 and 40 mg/kg) in female Sprague–Dawley rats. Dose-dependent metabolic alterations induced by risperidone after 6 weeks of treatment were revealed. Concomitant to weight gain and increased liver weight, an adverse lipid profile with an elevated triglyceride level was observed in the high exposure group, administered a 40 mg/kg dose repeatedly, while the low dose exposure group, administered a 20 mg/kg dose, developed weight gain without alterations in the lipid profile and adipokine levels. An initial peak in leptin serum level after the higher dose was observed in the absence of weight gain. This finding may indicate that the metabolic alterations observed in this study are not consequent to body weight gain. Taken together, these data may support the primary effects of atypical antipsychotics on peripheral tissues.

Links

ROZV/24/LF/2016, interní kód MU

Name: LF - Příspěvek IP 2016

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

HORSKÁ, Kateřina, Jana RUDÁ, Michal KARPISEK, Radka OPATŘILOVÁ, Pavel SUCHÝ and Hana KOTOLOVÁ. Depot risperidone-induced adverse metabolic alterations in female rats. Journal of Psychopharmacology. London: SAGE Publications Ltd., 2017, vol. 31, No 4, p. 487-499. ISSN 0269-8811. Available from: https://dx.doi.org/10.1177/0269881117691466.

@article{1373188,
   author = {Horská, Kateřina and Rudá, Jana and Karpisek, Michal and Opatřilová, Radka and Suchý, Pavel and Kotolová, Hana},
   article_location = {London},
   article_number = {4},
   doi = {http://dx.doi.org/10.1177/0269881117691466},
   keywords = {Adipokine; depot risperidone; leptin; lipid profile; Sprague-Dawley rats},
   language = {eng},
   issn = {0269-8811},
   journal = {Journal of Psychopharmacology},
   title = {Depot risperidone-induced adverse metabolic alterations in female rats},
   url = {http://journals.sagepub.com/doi/10.1177/0269881117691466},
   volume = {31},
   year = {2017}
}

TY  - JOUR
ID  - 1373188
AU  - Horská, Kateřina - Rudá, Jana - Karpisek, Michal - Opatřilová, Radka - Suchý, Pavel - Kotolová, Hana
PY  - 2017
TI  - Depot risperidone-induced adverse metabolic alterations in female rats
JF  - Journal of Psychopharmacology
VL  - 31
IS  - 4
SP  - 487-499
EP  - 487-499
PB  - SAGE Publications Ltd.
SN  - 02698811
KW  - Adipokine
KW  - depot risperidone
KW  - leptin
KW  - lipid profile
KW  - Sprague-Dawley rats
UR  - http://journals.sagepub.com/doi/10.1177/0269881117691466
L2  - http://journals.sagepub.com/doi/10.1177/0269881117691466
N2  - Atypical antipsychotics are associated with adverse metabolic effects including weight gain, increased adiposity, dyslipidaemia, alterations in glucose metabolism and insulin resistance. Increasing evidence suggests that metabolic dysregulation precedes weight gain development. The aim of this study was to evaluate alterations in adipokines, hormones and basic serum biochemical parameters induced by chronic treatment with depot risperidone at two doses (20 and 40 mg/kg) in female Sprague–Dawley rats. Dose-dependent metabolic alterations induced by risperidone after 6 weeks of treatment were revealed. Concomitant to weight gain and increased liver weight, an adverse lipid profile with an elevated triglyceride level was observed in the high exposure group, administered a 40 mg/kg dose repeatedly, while the low dose exposure group, administered a 20 mg/kg dose, developed weight gain without alterations in the lipid profile and adipokine levels. An initial peak in leptin serum level after the higher dose was observed in the absence of weight gain. This finding may indicate that the metabolic alterations observed in this study are not consequent to body weight gain. Taken together, these data may support the primary effects of atypical antipsychotics on peripheral tissues.
ER  -

HORSKÁ, Kateřina, Jana RUDÁ, Michal KARPISEK, Radka OPATŘILOVÁ, Pavel SUCHÝ and Hana KOTOLOVÁ. Depot risperidone-induced adverse metabolic alterations in female rats. \textit{Journal of Psychopharmacology}. London: SAGE Publications Ltd., 2017, vol.~31, No~4, p.~487-499. ISSN~0269-8811. Available from: https://dx.doi.org/10.1177/0269881117691466.

Detailed Information on Publication Record